Cargando…

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells

OBJECTIVES: Triple negative breast cancer (TNBC) lacks specific drug targets and remains challenging. Palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor is approved for metastatic estrogen receptor (ER)-positive and human epithermal growth factor 2 (HER2)-negative breast cancer. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chun-Yu, Lau, Ka-Yi, Hsu, Chia-Chi, Chen, Ji-Lin, Lee, Chia-Han, Huang, Tzu-Ting, Chen, Yi-Ting, Huang, Chun-Teng, Lin, Po-Han, Tseng, Ling-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737960/ https://www.ncbi.nlm.nih.gov/pubmed/29261702 http://dx.doi.org/10.1371/journal.pone.0189007

Ejemplares similares

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
por: Huang, Yajing, et al.
Publicado: (2020)

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression
por: Huang, Tzu-Ting, et al.
Publicado: (2020)

High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
por: Hsieh, Yu-Ting, et al.
Publicado: (2021)

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

HSulf-1 and palbociclib exert synergistic antitumor effects on RB-positive triple-negative breast cancer
por: Chen, Fengxia, et al.
Publicado: (2020)

Sorafenib analogue SC‐60 induces apoptosis through the SHP‐1/STAT3 pathway and enhances docetaxel cytotoxicity in triple‐negative breast cancer cells
por: Liu, Chun‐Yu, et al.
Publicado: (2017)

Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
por: Lin, Yi-Ting, et al.
Publicado: (2021)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

Small interfering RNA targeting N-cadherin regulates cell proliferation and migration in enzalutamide-resistant prostate cancer
por: Lu, Cheng-Hsin, et al.
Publicado: (2022)

Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib
por: Ji, Wenfei, et al.
Publicado: (2019)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
por: Cochrane, Dawn R, et al.
Publicado: (2014)

Complete androgen insensitivity syndrome caused by the c.2678C>T mutation in the androgen receptor gene: A case report
por: Wang, Ka-Na, et al.
Publicado: (2021)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
por: Tseng, Chi-Shin, et al.
Publicado: (2023)

Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor
por: Wang, Bi-Juan, et al.
Publicado: (2022)

Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2016)

Correction: Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Circulating androgen regulation by androgen-catabolizing gut bacteria in male mouse gut
por: Hsiao, Tsun-Hsien, et al.
Publicado: (2023)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study
por: Lin, Hsin-Le, et al.
Publicado: (2022)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
por: Alumkal, Joshi J., et al.
Publicado: (2020)

Senescence in Monocytes Facilitates Dengue Virus Infection by Increasing Infectivity
por: Hsieh, Tzu-Han, et al.
Publicado: (2020)

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
por: Choupani, Edris, et al.
Publicado: (2022)

Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth
por: Lin, Chiao-Yun, et al.
Publicado: (2019)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Palbociclib Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells via RB-Independent STAT3 Phosphorylation
por: Xiang, Wenjing, et al.
Publicado: (2022)

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
por: Huang, Yu-Hsiang, et al.
Publicado: (2018)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2016)

Computed Tomography-Guided Methylene Blue Localization: Single vs. Multiple Lung Nodules
por: Lin, Chia-Ying, et al.
Publicado: (2021)

Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
por: Febres-Aldana, Christopher A., et al.
Publicado: (2022)

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
por: Guarducci, Cristina, et al.
Publicado: (2018)

Fish Oil and Selenium with Doxorubicin Modulates Expression of Fatty Acid Receptors and Selenoproteins, and Targets Multiple Anti-Cancer Signaling in Triple-negative Breast Cancer Tumors
por: Guo, Chih-Hung, et al.
Publicado: (2022)

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
por: Lin, Changyi, et al.
Publicado: (2020)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vilfb55u02rl9j218n7gidf7pr